Zuclopenthixol-associated neutropenia and thrombocytopenia

Boaz Hirshberg, Alexander Gural, Yoseph Caraco*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


OBJECTIVE: To report a case of neutropenia and thrombocytopenia secondary to use of zuclopenthixol in a schizophrenic patient. CASE SUMMARY: A 66-year-old white man with chronic schizophrenia was referred to the hospital due to neutropenia and thrombocytopenia that developed shortly after initiation of zuclopenthixol therapy. Prior to zuclopenthixol administration, his white blood cell and platelet counts were 8.5 x 109 cells/L3 and 305 cells x 109/L, respectively. Progressive reduction in leukocyte and platelet counts occurred, reaching a nadir of 2.9 x 109 cells/L3 (granulocytes 18.9%) and 109 cells x 109/L, respectively. Zuclopenthixol was discontinued on admission, resulting in complete recovery within the next five days. DISCUSSION: Neutropenia and thrombocytopenia are well-known complications of antipsychotic drug therapy. Zuclopenthixol, a well-established antipsychotic agent, has relatively few adverse effects. The rapid decrease of white blood cell and platelet counts following the initiation of zuclopenthixol, as well as the rapid recovery, implicate zuclopenthixol as the predominant cause for neutropenia and thrombocytopenia in this patient. CONCLUSIONS: Although neutropenia and thrombocytopenia are rare complications of zuclopenthixol therapy, monitoring blood counts in patients receiving this agent seems to be justified.

Original languageAmerican English
Pages (from-to)740-742
Number of pages3
JournalAnnals of Pharmacotherapy
Issue number6
StatePublished - 2000
Externally publishedYes


  • Neutropenia
  • Thrombocytopenia
  • Zuclopenthixol


Dive into the research topics of 'Zuclopenthixol-associated neutropenia and thrombocytopenia'. Together they form a unique fingerprint.

Cite this